JMY Inhibitors

JMY inhibitors encompass a diverse chemical class that primarily includes compounds interfering with actin dynamics and p53 signaling. These inhibitors often target proteins or cellular processes that are upstream or downstream of JMY's function. For instance, inhibitors like Pifithrin-α directly interact with p53, a protein that JMY coactivates, leading to reduced transcriptional activation of p53-responsive genes. Similarly, compounds that target the actin cytoskeleton, such as Latrunculin A, Swinholide A, and Cytochalasin D, disrupt the polymerization and dynamics of actin filaments. Since JMY can act as an actin nucleation factor and promote the assembly of actin filaments, these compounds can indirectly inhibit JMY's function in actin polymerization.

Other chemicals, including kinase inhibitors like Y-27632 and Blebbistatin, modulate the activity of kinases involved in actin filament stabilization and myosin function, respectively. Inhibition of these kinases leads to alterations in the actin cytoskeleton and cell motility, processes in which JMY is implicated. Additionally, CCG-1423 and Thiazovivin, which are inhibitors of Rho signaling and ROCK kinases, respectively, also have the capacity to influence actin architecture, thereby affecting JMY's roles. CK-666 and SMIFH2, on the other hand, are specific inhibitors of actin nucleation pathways distinct from JMY but can still impact the overall dynamics of actin filament formation that JMY could influence. Overall, the chemical class of JMY inhibitors is characterized by a wide range of structures and targets, but with a common theme of influencing the cellular pathways and processes in which JMY is a key player.